26-Year-Old Female with Worsening Psoriasis Who Is Planning Pregnancy
A 26-year-old woman presents with worsening diffuse-body psoriasis while on a regimen of topical steroids and ultraviolet B phototherapy. She qualifies for treatment with biologics, but she is also planning pregnancy. Certolizumab pegol, a novel tumor necrosis factor inhibitor that does not undergo transplacental transport, is considered the safest biologic with regards to fetal outcomes. After counseling on the risks and benefits of biologic therapy, the patient chose to switch her regimen to certolizumab pegol prior to becoming pregnant.
KeywordsPregnancy Fetus Certolizumab pegol Biologics Ultraviolet B Topical corticosteroids
- 3.Vena GA, Cassano N, Bellia G, Colombo D. Psoriasis in pregnancy: challenges and solutions. Psoriasis (Auckl). 2015;5:83–95.Google Scholar
- 7.Chi CC, Lee CW, Wojnarowska F, Kirtschig G. Safety of topical corticosteroids in pregnancy. Cochrane Database Syst Rev. 2009;3:CD007346.Google Scholar
- 11.Johansen CB, Jimenez-Solem E, Haerskjold A, Sand FL, Thomsen SF. The use and safety of TNF inhibitors during pregnancy in women with psoriasis: a review. Int J Mol Sci. 2018;19(5):pii: E1349.Google Scholar
- 16.Gottlieb AB, Blauvelt A, Thaçi D, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). J Am Acad Dermatol. 2018;79(2):302–314.e6.CrossRefGoogle Scholar